Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)

SHE:001367 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	473.23	470.54	396.28	421.14	386.79	283.41
Other Revenue	0.97	0.97	1.17	1.64	2.19	1.39
Revenue	474.19	471.51	397.45	422.78	388.98	284.8
Revenue Growth (YoY)	16.71%	18.63%	-5.99%	8.69%	36.58%	6.94%
Cost of Revenue	277.49	281.91	237.4	266.52	236.12	173.83
Gross Profit	196.7	189.6	160.05	156.26	152.87	110.97
Selling, General & Admin	43.44	40.65	35.72	32.25	32.94	27.19
Research & Development	32.94	27.78	18.84	15.77	12.07	10.83
Other Operating Expenses	5.55	4.36	4.16	2.13	3.11	2.59
Operating Expenses	81.92	72.88	59.15	51.24	47.85	39.97
Operating Income	114.78	116.72	100.9	105.02	105.02	71
Interest Expense	-0.37	-0.37	-0.03	-0.07	-0.1	-
Interest & Investment Income	16.43	18.41	15.62	3.55	2.25	4.22
Currency Exchange Gain (Loss)	3.32	3.32	0.87	8.37	-2.17	-3.76
Other Non Operating Income (Expenses)	-0.36	-0.24	-0.19	0.05	-0.4	-0.3
EBT Excluding Unusual Items	133.81	137.85	117.17	116.93	104.59	71.17
Gain (Loss) on Sale of Investments	-	-	-	-3.85	0.74	-
Gain (Loss) on Sale of Assets	-0.12	-	-0.24	-	-	-
Asset Writedown	-0.94	-1.23	-0.96	-1.21	-0.67	-0.24
Other Unusual Items	6.27	5.11	4.71	11.91	3.86	2.64
Pretax Income	139.08	141.79	120.68	123.78	108.52	73.57
Income Tax Expense	18.69	19.23	16.01	16.19	14.52	10.75
Net Income	120.39	122.56	104.67	107.59	94	62.83
Net Income to Common	120.39	122.56	104.67	107.59	94	62.83
Net Income Growth	6.48%	17.09%	-2.72%	14.46%	49.62%	-8.89%
Shares Outstanding (Basic)	149	149	137	112	112	112
Shares Outstanding (Diluted)	151	150	137	112	112	112
Shares Change (YoY)	2.99%	9.35%	22.74%	-0.02%	-	-0.16%
EPS (Basic)	0.81	0.82	0.76	0.96	0.84	0.56
EPS (Diluted)	0.80	0.82	0.76	0.96	0.84	0.56
EPS Growth	3.39%	7.09%	-20.74%	14.68%	49.60%	-8.89%
Free Cash Flow	88.91	102.41	23.17	54.76	73.72	55.48
Free Cash Flow Per Share	0.59	0.68	0.17	0.49	0.66	0.50
Dividend Per Share	0.115	0.115	0.228	-	-	-
Dividend Growth	-49.65%	-49.65%	-	-	-	-
Gross Margin	41.48%	40.21%	40.27%	36.96%	39.30%	38.96%
Operating Margin	24.20%	24.75%	25.39%	24.84%	27.00%	24.93%
Profit Margin	25.39%	25.99%	26.33%	25.45%	24.16%	22.06%
Free Cash Flow Margin	18.75%	21.72%	5.83%	12.95%	18.95%	19.48%
EBITDA	130.43	131.76	113.52	118.59	117.37	81.64
EBITDA Margin	27.51%	27.94%	28.56%	28.05%	30.17%	28.67%
D&A For EBITDA	15.65	15.04	12.62	13.56	12.35	10.64
EBIT	114.78	116.72	100.9	105.02	105.02	71
EBIT Margin	24.20%	24.75%	25.39%	24.84%	27.00%	24.93%
Effective Tax Rate	13.44%	13.56%	13.26%	13.08%	13.38%	14.61%
Revenue as Reported	474.19	471.51	397.45	422.78	388.98	284.8

Updated Oct 17, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.